ECSP034647A - Uso de factor vii actividad de coagulacion para tratar sangrados graves inducidos por terapia - Google Patents

Uso de factor vii actividad de coagulacion para tratar sangrados graves inducidos por terapia

Info

Publication number
ECSP034647A
ECSP034647A EC2003004647A ECSP034647A ECSP034647A EC SP034647 A ECSP034647 A EC SP034647A EC 2003004647 A EC2003004647 A EC 2003004647A EC SP034647 A ECSP034647 A EC SP034647A EC SP034647 A ECSP034647 A EC SP034647A
Authority
EC
Ecuador
Prior art keywords
factor vii
therapy
coagulation activity
serious bleeding
treat serious
Prior art date
Application number
EC2003004647A
Other languages
English (en)
Inventor
Wolfgang Wienen
Jean Marie Stassen
Cord Skamira
Gerhard Heusel
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of ECSP034647A publication Critical patent/ECSP034647A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Los sangrados graves inducidos por terapia trombolítica/fibrinólitica, que incluyen hemorragias intracraneale, se tratan al administrar a un paciente que sufre de estos sangrados una cantidad efectiva de un factor VII activado (VIIa) de coagulación o de un derivado funcional del mismo.
EC2003004647A 2000-12-21 2003-06-11 Uso de factor vii actividad de coagulacion para tratar sangrados graves inducidos por terapia ECSP034647A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00128252A EP1216709A1 (en) 2000-12-21 2000-12-21 Use of activated coagulation factor VII for treating thrombolytic therapy-induced major bleedings

Publications (1)

Publication Number Publication Date
ECSP034647A true ECSP034647A (es) 2003-07-25

Family

ID=8170769

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004647A ECSP034647A (es) 2000-12-21 2003-06-11 Uso de factor vii actividad de coagulacion para tratar sangrados graves inducidos por terapia

Country Status (25)

Country Link
US (2) US20040087502A1 (es)
EP (2) EP1216709A1 (es)
JP (1) JP2004516273A (es)
KR (1) KR20030063454A (es)
CN (1) CN1482919A (es)
AT (1) ATE353666T1 (es)
AU (2) AU2638602A (es)
BR (1) BR0116151A (es)
CA (1) CA2431986A1 (es)
CY (1) CY1106363T1 (es)
CZ (1) CZ300670B6 (es)
DE (1) DE60126650T2 (es)
DK (1) DK1343523T3 (es)
EC (1) ECSP034647A (es)
ES (1) ES2280429T3 (es)
HU (1) HUP0302574A3 (es)
IL (1) IL155886A0 (es)
MX (1) MXPA03005641A (es)
NZ (1) NZ549850A (es)
PL (1) PL205878B1 (es)
PT (1) PT1343523E (es)
RU (1) RU2286796C2 (es)
SI (1) SI1343523T1 (es)
WO (1) WO2002049665A2 (es)
ZA (1) ZA200304140B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005123118A1 (en) * 2004-06-21 2005-12-29 Novo Nordisk Health Care Ag Use of factor viia or factor viia equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ich)
RU2396086C2 (ru) * 2004-09-10 2010-08-10 Фармаоригин Апс Способы лечения трахеального, бронхиального или альвеолярного кровотечения или кровохарканья
US20090156481A1 (en) * 2005-07-15 2009-06-18 Novo Nordisk Healthcare A/G Use of Factor VIIa or Factor VIIa Equivalents for Preventing or Attenuating Haemorrhage Growth, and/or Oedema Generation Following Intracerebral Haemorrhage (ICH) in Patients Treated with Antiplatelet Therapy
JP2011509978A (ja) 2008-01-18 2011-03-31 ノボ ノルディスク ヘルス ケア アーゲー 選択されたＩＣＨ患者亜集団における脳内出血（ＩＣＨ）後の出血拡大、及び／又は浮腫生成の予防又は減弱のための、第ＶＩＩａ因子又は第ＶＩＩａ因子等価物の使用
RU2552339C1 (ru) * 2014-02-19 2015-06-10 Общество с ограниченной ответственностью фирма "Технология-Стандарт" Способ профилактики кровотечений, вызванных применением стрептокиназы, в эксперименте

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4382082A (en) * 1980-12-18 1983-05-03 Uop Inc. Recovery of cobalt values by absorption from ammoniacal solution
ZA862768B (en) * 1985-04-17 1986-12-30 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5374617A (en) * 1992-05-13 1994-12-20 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with FVIIa
US5846517A (en) * 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
AU7907398A (en) * 1997-06-23 1999-01-04 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function

Also Published As

Publication number Publication date
PL205878B1 (pl) 2010-06-30
EP1216709A1 (en) 2002-06-26
US20080286259A1 (en) 2008-11-20
ES2280429T3 (es) 2007-09-16
PL361855A1 (en) 2004-10-04
CN1482919A (zh) 2004-03-17
DE60126650T2 (de) 2007-10-31
JP2004516273A (ja) 2004-06-03
BR0116151A (pt) 2003-10-21
ATE353666T1 (de) 2007-03-15
KR20030063454A (ko) 2003-07-28
WO2002049665A3 (en) 2002-09-26
EP1343523A2 (en) 2003-09-17
PT1343523E (pt) 2007-03-30
HUP0302574A2 (hu) 2003-10-28
IL155886A0 (en) 2003-12-23
AU2638602A (en) 2002-07-01
CY1106363T1 (el) 2011-10-12
CZ300670B6 (cs) 2009-07-15
SI1343523T1 (sl) 2007-04-30
US20040087502A1 (en) 2004-05-06
EP1343523B1 (en) 2007-02-14
HUP0302574A3 (en) 2010-01-28
NZ549850A (en) 2008-04-30
RU2286796C2 (ru) 2006-11-10
AU2002226386B2 (en) 2005-12-22
WO2002049665A2 (en) 2002-06-27
CA2431986A1 (en) 2002-06-27
ZA200304140B (en) 2004-04-22
CZ20031743A3 (cs) 2003-11-12
DE60126650D1 (de) 2007-03-29
RU2003122362A (ru) 2005-02-10
MXPA03005641A (es) 2004-12-03
DK1343523T3 (da) 2007-04-10

Similar Documents

Publication Publication Date Title
NZ520083A (en) The modification of a patient's blood with ultra-violet light for the treatment of congestive heart failure
MXPA03000043A (es) Promocion de la salud en todo el cuerpo.
BR0111800A (pt) Combinações de inibidores de depeptidil peptidase iv e outros agentes antidiabéticos para o tratamento de diabete mellitus
BR0108977A (pt) Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina
CY1107054T1 (el) Ενωσεις διτοσυλικου αλατος κιναζολινης
DE60034344D1 (de) Methode zur behandlung der symptome hormoneller veränderungen, einschliesslich hitzewallungen
AR032879A1 (es) Compuestos derivados de ecteinascidina, sus composiciones farmaceuticas, sus usos y metodo de tratamiento de tumores
DE50208008D1 (de) Tiotropiumsalze zur behandlung von entzündlichen erkrankungen
ES2194392T3 (es) Derivados alfa-aminoamidicos utiles como agentes analgesicos.
NO20021035L (no) Fremgangsmåter for anvendelse av rasktvirkende selective serotonin gjenopptakningsinhibitorer for behandling av seksuelldysfunksjon
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
PT1216707E (pt) Novas utilizacoes terapeuticas para um smr-1-peptideo
ES2180933T3 (es) Inhibidor de la serina-proteasa.
BR0206237A (pt) Uso de um composto de carboestiril
AR021155A1 (es) Tratamiento de desordenes neuroticos
AR044315A1 (es) Agente para prevenir y/o tratar enfermedades acompañadas de alteraciones de tejidos que comprende un polipeptido
ECSP034647A (es) Uso de factor vii actividad de coagulacion para tratar sangrados graves inducidos por terapia
ES2170798T3 (es) Benzopiranos y su uso como agentes terapeuticos.
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
HRP20040383B1 (hr) Ne-neurotoksični faktori aktivacije plazminogena za liječenje moždanog udara
ES2061610T3 (es) Nuevos derivados hidrogenados de antibiotico a/16686.
DE69817798D1 (de) Gegen picorna-viren gerichtete verbindungen, zusammensetzungen die diese verbindungen enthalten und methoden zu ihrer anwendung
BR0115881A (pt) Emprego de compostos ciclohexanona substituìdos de 6-dimetilaminometil-1-fenil para a terapia da incontinência urinária
BR0111740A (pt) Terapia combinada contra tumores que compreende derivados de distamicina acriloila substituìda e agentes de alquilação
EA200001058A1 (ru) Новые способы лечения нервных расстройств